Acrux Ltd
ASX:ACR

Watchlist Manager
Acrux Ltd Logo
Acrux Ltd
ASX:ACR
Watchlist
Price: 0.015 AUD 7.14% Market Closed
Market Cap: AU$6.2m

Operating Margin

-124.4%
Current
Declining
by 46.8%
vs 3-y average of -77.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-124.4%
=
Operating Income
AU$-5.6m
/
Revenue
AU$4.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-124.4%
=
Operating Income
AU$-5.6m
/
Revenue
AU$4.5m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Acrux Ltd
ASX:ACR
5.7m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
269.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208B GBP
Loading...
CH
Novartis AG
SIX:NOVN
217.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.9B EUR
Loading...

Market Distribution

In line with most companies in Australia
Percentile
40th
Based on 3 951 companies
40th percentile
-124.4%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Acrux Ltd
Glance View

Market Cap
6.2m AUD
Industry
Pharmaceuticals

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.

ACR Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-124.4%
=
Operating Income
AU$-5.6m
/
Revenue
AU$4.5m
What is Acrux Ltd's current Operating Margin?

The current Operating Margin for Acrux Ltd is -124.4%, which is below its 3-year median of -77.6%.

How has Operating Margin changed over time?

Over the last 3 years, Acrux Ltd’s Operating Margin has increased from -187.8% to -124.4%. During this period, it reached a low of -187.8% on Jun 30, 2022 and a high of 0.9% on Jun 30, 2023.

Back to Top